29 Jul 19. Featured Paper
Manganese-enhanced MRI of the myocardium.
After gadolinium, manganese has the second highest paramagnetic moment and was one of the first MRI contrast agents assessed in humans.
Over the last 50 years, manganese-enhanced MRI (MEMRI) has emerged as a complementary approach enabling intracellular myocardial contrast imaging that can identify functional myocardium through its ability to act as a calcium analogue.
Early progress was limited by its potential to cause myocardial depression.
To overcome this problem, two clinical formulations of manganese were developed using either chelation (manganese dipyridoxyl diphosphate) or coadministration with a calcium compound (EVP1001-1, Eagle Vision Pharmaceuticals).
Preclinical studies have demonstrated the efficacy of MEMRI in quantifying myocardial infarction and detecting myocardial viability as well as tracking altered contractility and calcium handling in cardiomyopathy.
Recent clinical data suggest that MEMRI has exciting potential in the quantification of myocardial viability in ischaemic cardiomyopathy, the early detection of abnormalities in myocardial calcium handling, and ultimately, in the development of novel therapies for myocardial infarction or heart failure by actively quantifying viable myocardium.
The stage is now set for wider clinical translational study of this novel and promising non-invasive imaging modality.
Manganese-enhanced magnetic resonance imaging (MEMRI)